Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Oncol Rep. 2008 Jan;10(1):10-7.

The emerging role of lapatinib in HER2-positive breast cancer.

Author information

1
Department of Human Oncology, Allegheny General Hospital, Allegheny Cancer Center, Fifth Floor, 320 East North Avenue, Pittsburgh, PA 15212, USA.

Abstract

In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

PMID:
18366956
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center